Genetic Technology News

摘要

Avicena Huntington's Disease Trial Will Proceed; Two Compugen Peptides Block Disease Proteins; GTN Strategic Partners; Some Important Patents for You To Check; 4th Annual Innovations in New Product Development and Marketing 2008 Executive Mindxchange;GENENTECH OPTS FOR EXELIXIS ANTIC ANCER AGENT: Genentech Inc. (South San Francisco, CA) has exercised its option to further develop and commercialize compound XL518 from Exelixis Inc. The compound is a selective inhibitor of MEK (mitogen-activated protein (MAP) extracellular signal-regulated kinase (ERK) kinase), a member of the MAP pathway, one of the most frequently dysregulated pathways in human tumors.